EMCITATE® (tiratricol)
EMCITATE® Approved Product Information
EMCITATE® (tiratricol) is indicated for the treatment of peripheral thyrotoxicosis in adults and pediatric patients with MCT8 deficiency
EMCITATE® (tiratricol) is indicated for the treatment of peripheral thyrotoxicosis in patients with MCT8 deficiency from birth
The information on this page is intended for healthcare professionals.
Availability, approved indications and prescribing information may differ between countries. Healthcare professionals should consult the locally approved product information before prescribing.
Clinical Trials & Managed Access
Whenever possible, participation in an ongoing clinical trial is the preferred route for accessing investigational medicines. In certain circumstances, patients may be able to access Egetis therapies before they are commercially available or reimbursed in their country
Explore